EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model

Siavash Mashhouri, Amirhossein Rahmati, Ako Azimi, Roy A Fava, Ismail Hassan Ismail, John Walker, Shokrollah Elahi

Cellular Oncology · 2024-10 · 47 (5) · 1735-1756

DOI: 10.1007/s13402-024-00950-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 26.04.2024. Verfasst von Siavash Mashhouri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dentistry, Division of Foundational Sciences, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada. Hauptthemen laut MEDLINE: Lectins, C-Type, beta-Glucans, Tumor Microenvironment, Mice, Inbred C57BL. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Cancer Research Society, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Acquired resistance to immune checkpoint blockers (ICBs) is a major barrier in cancer treatment, emphasizing the need for innovative strategies. Dectin-1 (gene Clec7a ) is a C-type lectin receptor best known for its ability to recognize β-glucan-rich structures in fungal cell walls. While Dectin-1 is expressed in myeloid cells and tumor cells, its significance in cancer remains the subject of controversy.

Methods

Using Celc7a-/- mice and curdlan administration to stimulate Dectin-1 signaling, we explored its impact. VISTA KO mice were employed to assess VISTA’s role, and bulk RNAseq analyzed curdlan effects on neutrophils.

Results

Our findings reveal myeloid cells as primary Dectin-1 expressing cells in the tumor microenvironment (TME), displaying an activated phenotype. Strong Dectin-1 co-expression/co-localization with VISTA and PD-L1 in TME myeloid cells was observed. While Dectin-1 deletion lacked protective effects, curdlan stimulation significantly curtailed B16-F10 tumor progression. RNAseq and pathway analyses supported curdlan’s role in triggering a cascade of events leading to increased production of pro-inflammatory mediators, potentially resulting in the recruitment and activation of immune cells. Moreover, we identified a heterogeneous subset of Dectin-1+ effector T cells in the TME. Similar to mice, human myeloid cells are the prominent cells expressing Dectin-1 in cancer patients.

Conclusion

Our study proposes Dectin-1 as a potential adjunctive target with ICBs, orchestrating a comprehensive engagement of innate and adaptive immune responses in melanoma. This innovative approach holds promise for overcoming acquired resistance to ICBs in cancer treatment, offering avenues for further exploration and development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lectins, C-Typebeta-GlucansTumor MicroenvironmentMice, Inbred C57BLColorectal NeoplasmsAnimalsMiceMice, KnockoutDisease Models, AnimalMelanoma, ExperimentalCell Line, TumorHumansMelanomaMyeloid CellsSignal TransductionDectin-1

Stichwörter der Autor:innen

Dectin-1 KO miceDectin-1+ Myeloid cellsDectin-1+ T cellsPD-L1+Dectin-1+ myeloid cellsVISTA KO mice

Substanzen

Lectins, C-Typebeta-GlucansDectin-1curdlan

Autor:innen und Institutionen

  • Department of Dentistry, Division of Foundational Sciences, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
  • Department of Veterans Affairs Medical Center, Research Service, White River Junction, VT, USA.
  • Department of Medicine, Geisel School of Medicine at Dartmouth, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
  • Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
  • Biophysics Department, Faculty of Science, Cairo University, Giza, 12613, Egypt.
  • Department of Dentistry, Division of Foundational Sciences, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada. elahi@ualberta.ca.

Förderung

  • CIHR
  • Cancer Research Society
  • Canadian Institutes of Health Research

Zitieren

APA

Mashhouri, S., Rahmati, A., Azimi, A., Fava, R. A., Ismail, I. H., Walker, J., & Elahi, S. (2024). Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model. Cellular Oncology, 47(5), 1735-1756. https://doi.org/10.1007/s13402-024-00950-w

Vancouver

Mashhouri S, Rahmati A, Azimi A, Fava RA, Ismail IH, Walker J, et al. Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model. Cellular Oncology. 2024;47(5):1735-1756. doi:10.1007/s13402-024-00950-w

BibTeX
@article{Mashhouri2024,
  author = {Mashhouri, Siavash and Rahmati, Amirhossein and Azimi, Ako and Fava, Roy A and Ismail, Ismail Hassan and Walker, John and Elahi, Shokrollah},
  title = {Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model},
  journal = {Cellular Oncology},
  year = {2024},
  volume = {47},
  number = {5},
  pages = {1735--1756},
  doi = {10.1007/s13402-024-00950-w}
}
Kostenlos starten →